Trastuzumab

Drug Profile

Trastuzumab

Alternative Names: Anti-c-erbB-2 monoclonal antibody; Anti-erbB-2- monoclonal antibody; Anti-HER-2 monoclonal antibody; Anti-p185HER-2 monoclonal antibody; HER-2; HER-2 human monoclonal antibody; HER-2 MAb; HER-2 monoclonal antibody; HER-2 murine monoclonal antibody; HER-2/neu MAb; HER-2/neu monoclonal antibody; Herceptin; Monoclonal antibody 4D5; R 597; RG597

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Genentech; Memorial Sloan-Kettering Cancer Center
  • Developer Chugai Pharmaceutical; Dana-Farber Cancer Institute; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; Genentech; Northwestern University; Roche; Sanofi; West German Study Group
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer
  • Phase II Colorectal cancer
  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Urogenital cancer

Most Recent Events

  • 13 Mar 2017 Mylan withdraws its Inter Partes Review (IPR) challenges against two US Genentech patents (No. 6 407 213 and 6 331 415)
  • 24 Jan 2017 Roche completes a phase II trial for Gastric cancer (combination therapy) in Germany (NCT01472029)
  • 11 Jan 2017 Genentech collaborates with NCI Formulary to co-develop trastuzumab in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top